The House Energy and Commerce Health Subcommittee today approved legislation that would prohibit Medicare and private health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance. Some health insurance contracts prevent pharmacists from informing patients when the cash price for their prescription costs less than their insurance cost-sharing arrangement unless the individual asks. The subcommittee also approved a bill that would allow the Centers for Medicare & Medicaid Services to provide certain drug rebate information to the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment Advisory Commission to inform their recommendations on drug-related issues.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Chairperson's File
Public
One of the most rewarding parts of being an AHA member and serving on the board is building relationships with other leaders who share a passion for making…
Headline
The AHA Dec. 11 expressed support for the reintroduction of the Future Advancement of Academic Nursing, bicameral legislation that would increase nursing…
Headline
The Centers for Medicare & Medicaid Services released guidance Dec. 8 for states implementing Medicaid community engagement requirements outlined by the…